Research programme: scanning unnatural protease resistant peptides - EvoRxAlternative Names: EVO-004; SUPR 4; SUPR-18F
Latest Information Update: 22 Aug 2016
At a glance
- Originator EvoRx
- Developer EvoRx; University of Texas M. D. Anderson Cancer Center
- Class Imaging agents; Peptide diagnostics; Radiopharmaceutical diagnostics
- Mechanism of Action Computer-assisted image interpretation enhancers; Image enhancers; Positron-emission tomography enhancers
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Breast cancer